AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Current stock price: 12,510.00 pence

12-month change: up 7.4%

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.